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Complement (C) is key to host homeostasis and C dysfunction can manifest in disease.  For 
example, atypical haemolytic uraemic syndrome (aHUS), a rare kidney disease, can arise from 
impaired regulation or gain of function changes in the alternative pathway. Indeed, in the Newcastle 
aHUS cohort, there are several families with a C3 change suspected of precipitating disease. To 
date, mouse models of aHUS have focused on altering factor H. To test the mechanisms behind C3 
changes and disease, we hypothesized that a single amino acid change in C3 found in man, like 
D1115N, when transferred to mouse C3 would result in aHUS or aHUS-like disease.  
Using recombinant mouse C3 and a D1115N point mutant (among others), we established that 
C3D1115N was refractory to fluid phase breakdown and bound weakly to mouse mini-FH. A conditional 
knock-in mouse was commissioned. EM analysis of kidney from constitutively expressing 
homozygous C3D1115N mice at day 7 postpartum (P7) revealed endothelial injury and wrinkling of the 
basement membrane, consistent with ischemia precipitated by a thrombotic microangiopathy (TMA). 
Histological analysis of kidney from homozygote C3D1115N mice (P28) revealed extensive capillary 
loop dilatation due to micro-aneurysm formation, mesangiolysis, and segmental double contour 
appearance of capillary walls consistent with a chronic TMA. C3D1115N homozygote mice with active 
disease exhibit haematuria, thrombocytopenia, elevated creatinine and blood films show evidence 
of haemolysis. Collectively, these features demonstrate an aHUS phenotype, as found in man. 
Circulating plasma levels of activated C3 are higher in mice with active disease, compared to litter 
mate matched controls, and immunofluorescence studies have confirmed C3 deposition within the 
kidney which is distinct in its granular appearance (unlike that noted in mice devoid of FH which 
display a C3G-like phenotype).  Furthermore, significant membrane attack complex is noted in the 
glomerulus of homozygous C3D1115N mice, suggesting that C5 blockade could be used as an 
intervention in this model. These experiments are ongoing.   
In conclusion, a unique mouse model of aHUS based on a single amino acid change in mouse C3 
(D1115N) has been generated. It provides an ideal model to test future therapeutics designed to 
treat complement mediate TMA, to combine with other genetic or environmental changes and to 
understand the role of hyperactive complement in immune homeostasis in health and disease.  
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